Last updated: September 1, 2026
Myfembree, the fixed-dose combination of relugolix, estradiol and norethindrone acetate, is an oral GnRH antagonist product marketed in the United States by AbbVie under a collaboration originating with Myovant Sciences. The FDA approved it in 2021 for heavy menstrual bleeding associated with uterine fibroids and in 2022 for moderate-to-severe pain associated with endometriosis.[1] Its commercial trajectory depends on three factors: expansion beyond the initial fibroid market, adoption as an alternative to injectable GnRH therapies and the timing of generic entry against a layered patent estate.
What is Myfembree and how does the triple combination work?
Myfembree combines three active ingredients with complementary pharmacology:
| Component |
Pharmacologic role |
Commercial purpose |
| Relugolix |
Oral GnRH receptor antagonist |
Suppresses ovarian estrogen and progesterone production |
| Estradiol |
Estrogen add-back therapy |
Reduces hypoestrogenic effects and limits bone loss |
| Norethindrone acetate |
Progestin add-back therapy |
Protects the endometrium from unopposed estrogen |
Relugolix produces rapid, reversible suppression of gonadotropins without the initial flare associated with GnRH agonists. Estradiol and norethindrone acetate allow continued treatment while mitigating vasomotor symptoms and other consequences of estrogen deprivation.
The FDA-approved dose is one tablet once daily. The label limits treatment to 24 months because of concerns about bone mineral density loss. Myfembree is contraindicated in patients with thrombotic or thromboembolic disorders, certain hormone-sensitive cancers, liver disease and selected cardiovascular risk profiles.[1]
What FDA approvals support the Myfembree market?
Myfembree has two approved indications, giving it broader market coverage than products limited to uterine fibroids or endometriosis.
| FDA milestone |
Date |
Market significance |
| Initial approval for uterine fibroids |
May 2021 |
Opened the first commercial indication |
| Endometriosis indication |
August 2022 |
Expanded the addressable population and treatment duration opportunity |
| Dosage form |
Ongoing |
Once-daily oral tablet |
| Treatment restriction |
Ongoing |
Maximum 24 months because of bone-density risk |
The uterine-fibroid indication targets women with heavy menstrual bleeding who may otherwise receive hormonal contraceptives, tranexamic acid, GnRH agonists, surgery or uterine artery embolization. The endometriosis indication targets a chronic pain market with high treatment discontinuation and frequent use of hormonal suppression.
The endometriosis approval is commercially important because it creates a second demand base that is less dependent on surgical scheduling and acute bleeding control. It also places Myfembree in direct competition with oral GnRH antagonist regimens from AbbVie and other manufacturers.
How does Myfembree compare with Oriahnn and Orilissa?
Myfembree competes most directly with Oriahnn, Orilissa and injectable GnRH therapies.
| Product |
Active ingredient or combination |
Primary use |
Administration |
Key competitive issue |
| Myfembree |
Relugolix, estradiol, norethindrone acetate |
Fibroid bleeding and endometriosis pain |
Once daily |
Broad indications and simple dosing |
| Oriahnn |
Elagolix, estradiol, norethindrone acetate |
Fibroid-associated heavy bleeding |
Twice daily |
Earlier product with a narrower indication |
| Orilissa |
Elagolix |
Endometriosis pain |
Once or twice daily |
Requires separate management of hypoestrogenic effects |
| Lupron Depot |
Leuprolide acetate |
Fibroids, endometriosis and other conditions |
Injection |
Established physician familiarity but less convenient |
| Surgical therapy |
Various procedures |
Fibroids and endometriosis |
Procedure-based |
Higher upfront burden but may provide definitive treatment |
Myfembree has a formulation advantage over Orilissa because add-back therapy is included in the same tablet. Compared with Oriahnn, its once-daily schedule is simpler. Compared with injectable leuprolide, it avoids injection-site treatment and office-based administration.
The commercial disadvantage is that Myfembree remains subject to a 24-month treatment limit. It is therefore a disease-management product rather than a permanent intervention. Continued use depends on symptom recurrence, transition to other hormonal therapy or surgery.
How large is the addressable market for relugolix combination therapy?
The relevant market includes women with symptomatic uterine fibroids and endometriosis who require medical treatment but are not adequately managed by contraceptives, progestins, NSAIDs or existing GnRH therapy.
Uterine fibroids affect a large proportion of women during the reproductive years, but the reimbursed prescription market is smaller than the epidemiologic population. Treatment demand is concentrated among women with heavy menstrual bleeding, anemia, pain, fertility concerns or avoidance of hysterectomy and other procedures.
Endometriosis creates a recurring pain-management market. Patients often cycle through oral contraceptives, progestins, GnRH agonists, GnRH antagonists and surgery. Myfembree's value proposition is strongest for patients who need sustained ovarian suppression but cannot tolerate or do not want injectable treatment.
Market expansion is limited by:
- the 24-month treatment restriction;
- bone-density monitoring and counseling;
- thrombotic and cardiovascular contraindications;
- payer step therapy;
- competition from low-cost generic hormonal regimens;
- physician preference for surgery or established injectable products.
The product has greater commercial potential in endometriosis than in fibroids if physicians use it earlier in the treatment sequence. That shift would require favorable payer coverage and evidence that patients remain on therapy long enough to justify its higher branded cost.
What patents protect Myfembree?
Myfembree is protected by patents covering the relugolix combination, pharmaceutical composition and related use claims. The key U.S. patent identified in public product and patent materials is U.S. Patent No. 10,583,110, assigned to entities associated with Myovant and its development partners.[3]
| Patent protection category |
Subject matter |
Commercial effect |
| Combination composition |
Relugolix with estradiol and norethindrone acetate |
Protects the fixed-dose product |
| Pharmaceutical formulation |
Tablet composition and dosage configuration |
Raises the barrier to simple formulation copying |
| Method of treatment |
Use in uterine fibroids and endometriosis |
Supports method-of-use enforcement |
| Regulatory listings |
FDA Orange Book-listed patents |
Can trigger Paragraph IV litigation and a 30-month stay |
Patent term depends on the effective filing date, patent-term adjustment, patent-term extension and the specific Orange Book listing. Publicly available product materials indicate patent protection extending into the late 2030s for relevant Myfembree combination technology.[3] Exact generic entry timing must be determined from the current FDA Orange Book, patent-term calculations and any litigation settlements.
The estate is stronger than a single active-ingredient patent because a generic applicant would need to address the fixed-dose combination, the tablet formulation and listed methods of use. That does not eliminate an at-risk launch pathway. A generic company may challenge listed patents through an Abbreviated New Drug Application and Paragraph IV certification.
What is the Orange Book status of Myfembree?
FDA Orange Book listings are the principal regulatory mechanism for identifying patents that may delay approval of a drug product's ANDA. For Myfembree, the relevant analysis requires separating:
- patents listed against the fixed-dose product;
- patents covering relugolix itself;
- patents covering other relugolix products, such as Orgovyx;
- patents that may not be listed because they cover manufacturing or unapproved uses;
- regulatory exclusivity that is separate from patent protection.
A patent covering relugolix in another product does not automatically block a generic version of Myfembree. The ANDA applicant must address the patents listed for the referenced drug and the claims relevant to the proposed label.
FDA's Orange Book also identifies the expiration dates reported by the reference-product sponsor. Those dates can differ from the underlying nominal patent expiration date because of patent-term adjustment or extension. Any investment or litigation assessment should use the current Orange Book listing rather than a headline patent date.[2]
When does Myfembree lose exclusivity?
Myfembree's effective exclusivity period has several components.
Patent exclusivity
The primary commercial barrier is expected to extend into the late 2030s for the combination technology, subject to the exact patent claims and Orange Book status. Patent expiration does not guarantee immediate generic launch because FDA review, Paragraph IV litigation and settlement terms can alter entry timing.
Regulatory exclusivity
The initial 2021 approval and the 2022 endometriosis approval generated separate regulatory considerations. New clinical investigations supporting an indication may receive three years of exclusivity for the approved change if statutory requirements are met. Such exclusivity generally protects the specific change supported by new clinical investigations, not necessarily the entire product from all generic competition.
Relugolix's regulatory history also includes the separate Orgovyx and Oriahnn products. Exclusivity attached to one product does not automatically transfer to Myfembree.
Pediatric exclusivity
A six-month pediatric exclusivity period could extend applicable patent or regulatory protection if FDA requirements were completed and the agency granted the extension. Public product analysis should verify the current Orange Book before assigning a launch date.
Which companies are challenging Myfembree patents?
No broadly established public record identifies a final court judgment invalidating the principal Myfembree combination patents. Generic competition remains a future risk rather than a demonstrated current market event.
Potential challengers would include large generic manufacturers with experience in complex oral combinations, hormonal products and Paragraph IV litigation. The most credible applicants would likely have capabilities in:
- bioequivalence studies for multi-ingredient products;
- formulation development;
- controlled substances and reproductive-health regulatory compliance;
- patent litigation;
- payer contracting and specialty pharmacy distribution.
The absence of a public final invalidity decision supports a stronger near-term patent position. It does not establish that the estate would survive every validity or non-infringement challenge.
What patent litigation and settlements affect Myfembree?
Myfembree's risk profile is linked to litigation involving relugolix combination products and the broader collaboration between AbbVie, Myovant and Sumitomo Pharma.
AbbVie and Myovant entered a U.S. commercialization agreement in 2018 covering relugolix products, including the combination product that became Myfembree. Sumitomo Pharma acquired Myovant in 2023, retaining the commercial and development relationships associated with the product.[4][5]
A future settlement with an ANDA filer could establish an authorized-generic date, royalty arrangement or other launch restriction. No settlement date should be assumed without a publicly filed agreement, court docket or company disclosure.
How strong is the Myfembree patent estate?
The estate is commercially meaningful for four reasons.
First, the product is a fixed-dose combination rather than a simple relugolix tablet. Second, the formulation integrates add-back hormones into the same dosage form. Third, approved indications create method-of-use claims. Fourth, the expected patent horizon extends well beyond the initial 2021 approval.
The main weaknesses are equally clear. Combination patents can face obviousness challenges based on prior GnRH antagonist and add-back therapy literature. A challenger may argue that combining relugolix with estradiol and norethindrone acetate was predictable, that the claimed ranges lack adequate written description or that the formulation does not provide an unexpected result.
Patent strength is therefore moderate to strong for near-term commercial protection, but it is not equivalent to an unassailable monopoly through the late 2030s.
What is the financial trajectory for Myfembree?
Myfembree's revenue trajectory follows a typical specialty-launch pattern:
| Phase |
Period |
Financial driver |
| Launch |
2021 |
Initial fibroid indication, physician education and payer access |
| Indication expansion |
2022-2023 |
Endometriosis approval and broader patient targeting |
| Adoption build |
2023-2025 |
Repeat prescriptions, gynecology penetration and formulary expansion |
| Maturity |
Later decade |
Price pressure, treatment-duration limits and generic risk |
| Erosion |
After generic entry |
Rapid decline in branded volume and net price |
AbbVie does not consistently report Myfembree revenue as a separately disclosed major product line in its public financial reporting. That limits precise product-level revenue analysis. The company's financial statements place smaller products within broader portfolio categories, while Sumitomo Pharma and related disclosures provide additional but not always directly comparable information.[5][6]
The commercial trajectory is likely to depend more on prescription volume and persistence than on price increases. Myfembree has a higher revenue opportunity per treated patient than generic oral contraceptives, but payer controls can reduce net price and require failure on cheaper alternatives.
Key financial variables include:
- growth in endometriosis prescriptions;
- duration of therapy before discontinuation;
- prior authorization rates;
- co-pay support and gross-to-net deductions;
- conversion from injectable GnRH agonists;
- surgical deferral;
- the availability of generic alternatives;
- any future authorized-generic arrangement.
What generic launch scenarios exist for Myfembree?
Early Paragraph IV launch
A generic applicant could file a Paragraph IV certification against listed patents before their expiration dates. If the sponsor sued within 45 days, FDA approval could be stayed for up to 30 months, subject to court action and statutory exceptions.
Settlement-based launch
A settlement could permit launch before the latest patent expiration. Such agreements often include a defined entry date, but terms vary and may include royalty or supply provisions.
Post-expiration launch
If no earlier settlement occurs, generic entry could follow expiration of the relevant Orange Book patents and FDA approval. The combination's formulation complexity could slow the number of entrants relative to a conventional single-ingredient tablet.
At-risk launch
A generic company could launch before final resolution of patent litigation. That strategy would expose the applicant to damages and potential injunctive relief if the patent holder prevails.
The most likely erosion pattern is gradual rather than instantaneous if only a limited number of manufacturers initially obtain approval. Fixed-dose hormonal combinations can require more development work than standard oral generics.
What manufacturing and intellectual-property barriers exist?
The principal manufacturing barrier is reproducible production of a low-dose, three-active-ingredient tablet with consistent dissolution and bioequivalence. The product must maintain stability across the GnRH antagonist and both hormonal components.
Other barriers include:
- demonstrating bioequivalence for all active ingredients;
- controlling impurities and degradation products;
- matching the reference product's release characteristics;
- producing commercial-scale batches;
- meeting FDA requirements for reproductive-health products;
- addressing multiple patents in an ANDA certification;
- securing payer and pharmacy access after approval.
Manufacturing patents may create additional barriers even when they are not listed in the Orange Book. They can support separate litigation, although they generally do not create the same automatic FDA approval stay as a properly listed Orange Book patent.
How does Myfembree compare with other relugolix products?
Myfembree and Orgovyx use the same GnRH antagonist but address different diseases and dosage strategies.
| Product |
Manufacturer relationship |
Active ingredient |
Indication focus |
| Myfembree |
AbbVie and Sumitomo Pharma relationship |
Relugolix plus estradiol and norethindrone acetate |
Uterine fibroids and endometriosis |
| Orgovyx |
Myovant/Sumitomo Pharma |
Relugolix |
Advanced prostate cancer |
| Oriahnn |
AbbVie |
Elagolix plus add-back hormones |
Uterine fibroids |
| Orilissa |
AbbVie |
Elagolix |
Endometriosis pain |
Myfembree's add-back formulation gives it a differentiated clinical and commercial profile. Orgovyx generates a separate oncology revenue stream and has a different treatment population, payer structure and patent analysis. Patent overlap involving relugolix does not mean that one product's generic entry will automatically create generic entry for the other.
What is the geographic coverage and international opportunity?
The United States is the central commercial market for Myfembree. International opportunities depend on local approvals, licensing arrangements, reimbursement systems and the availability of competing GnRH products.
In markets where injectable GnRH agonists remain dominant, the oral route can support differentiation. In markets with extensive use of low-cost hormonal therapy or surgery, reimbursement may restrict uptake.
Patent coverage will vary by country. National phase patents, supplementary protection certificates, patent-term adjustments and local litigation outcomes can produce materially different entry dates across the United States, Europe, Japan and other markets. A U.S. Orange Book position does not establish equivalent protection abroad.
Key Takeaways
- Myfembree is a once-daily fixed-dose combination of relugolix, estradiol and norethindrone acetate.
- FDA approvals cover uterine-fibroid bleeding and endometriosis pain.
- The product competes with Oriahnn, Orilissa, Lupron Depot and surgical treatment.
- Its principal commercial strengths are oral dosing, integrated add-back therapy and two approved indications.
- Its main limitations are the 24-month treatment restriction, safety exclusions and payer pressure.
- U.S. patent protection for the combination is expected to extend into the late 2030s, subject to current Orange Book listings and patent-term calculations.
- No public final judgment establishing invalidity of the principal Myfembree combination protection is identified here.
- AbbVie does not consistently disclose Myfembree as a separately reported major revenue line, limiting precise product-level sales modeling.
- Revenue growth depends on endometriosis adoption, prescription persistence and conversion from injectable GnRH therapies.
- Generic erosion is more likely to be delayed by formulation complexity and patent litigation than for a conventional single-ingredient tablet.
FAQs
Is Myfembree the same drug as Orgovyx?
No. Both contain relugolix, but Myfembree includes estradiol and norethindrone acetate and is approved for uterine fibroids and endometriosis. Orgovyx is relugix monotherapy for advanced prostate cancer.
Can Myfembree be used indefinitely?
No. The FDA label limits treatment to 24 months because of bone mineral density concerns.
Does Myfembree have biosimilar risk?
No. Myfembree is a chemically synthesized small-molecule drug, so the relevant competition is generic rather than biosimilar competition.
Will generic relugolix automatically replace Myfembree?
No. A generic relugolix product without estradiol and norethindrone acetate would not be therapeutically or regulatorily identical to the Myfembree fixed-dose combination.
What would most increase Myfembree sales?
The largest commercial upside would come from earlier use in endometriosis, longer real-world persistence within the permitted treatment period and broader reimbursement without mandatory failure on lower-cost hormonal therapy.
References
- U.S. Food and Drug Administration. (2022). Myfembree prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,583,110.
- AbbVie Inc. (2018). AbbVie and Myovant Sciences collaboration announcement for relugolix programs.
- Sumitomo Pharma Co., Ltd. (2023). Completion of acquisition of Myovant Sciences Ltd.
- AbbVie Inc. (2024). Annual report and Form 10-K.
